Michel Detheux - Dec 31, 2022 Form 5 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Executive Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Dec 31, 2022
Transactions value $
$0
Form type
5
Date filed
3/10/2023, 06:50 PM
Previous filing
Apr 19, 2022
Next filing
Mar 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Gift $0 -264K -75% $0.00 88.1K Apr 15, 2022 Common Stock 264K $36.21 Direct F1, F2
transaction ITOS Stock Option (Right to Buy) Gift $0 +264K $0.00 264K Apr 15, 2022 Common Stock 264K $36.21 By MG3A F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.
F2 This stock option vests over four years, with 25% vesting on March 11, 2023 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.